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Abstract: Multiple sclerosis and neurodegenerative diseases in which cells of the central nervous system (CNS) are   
lost or damaged are rapidly increasing in frequency, and there is neither effective treatment nor cure to impede or arrest 
their destructive course. The Epstein-Barr virus is a human gamma-herpesvirus that infects more than 90% of the human 
population worldwide and persisting for the lifetime of the host. It is associated with numerous epithelial cancers, princi-
pally undifferentiated nasopharyngeal carcinoma and gastric carcinoma. Individuals with a history of symptomatic   
primary EBV infection, called infectious mononucleosis, carry a moderately higher risk of developing multiple sclerosis 
(MS). It is not known how EBV infection potentially promotes autoimmunity and central nervous system (CNS) tissue 
damage in MS. Recently it has been found that EBV isolates from different geographic regions have highly conserved 
BARF1 epitopes. BARF1 protein has the neuroprotective and mitogenic activity, thus may be useful to combat and  
overcome neurodegenerative disease. BARF1 protein therapy can potentially be used to enhance the neuroprotective  
activities by combinational treatment with anti-inflammatory antagonists and neuroprotectors in neural disorders.  
Keywords: Epstein-Barr Virus, neuroregeneration, chronic inflammatory disorders, multiple sclerosis. 
INTRODUCTION 
  Neurodegenerative diseases, in which cells of the central 
nervous system (CNS) are lost or damaged, affect millions of 
people worldwide, and as population demographics change, 
the frequency of these age-associated diseases is increasing 
rapidly. In Australia, the percentage of individuals over the 
age of 65 is incessantly rising, at a rate greater than the 
growth of the population as a whole; a trend that is expected 
to persist for years to come [1]. Alzheimer’s disease, Parkin-
son’s disease, multiple sclerosis, trauma, epilepsy, stroke and 
many others fall under the title of neurodegenerative disease, 
and are linked by another common thread: there is neither 
effective treatment nor cure to impede or arrest the destruc-
tive course of these devastating illnesses. The shift in age 
distribution and the prospect of cases escalating to epidemic 
proportions highlights the necessity for intensive research in 
this field. There is a strong need for improved therapies and 
novel concepts for the control and management of neurode-
generative diseases.  
  Extensive research has been carried out on the concept  
of neuroprotection, a strategy with the goal of reducing   
or preventing neuronal damage, apoptosis (programmed   
cell death), and the entry of inflammatory or autoreactive   
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lymphocytes (B/T cells) through the blood brain barrier 
(BBB) [2]. Significant evidence suggesting the anti-apoptotic 
role of BARF1, a viral oncogene, indicates its potential as a 
neuroprotector [3, 4]. The added appeal of this viral gene is 
the prospective mitogenic properties it pertains, which may 
assist in overcoming the limitations of the slow growing   
nature of neurons [5].  
  Neurodegenerative diseases share several common 
mechanisms that lead to clinical symptoms, and for the pur-
pose of this review, multiple sclerosis will be the focus, and 
a model for more detailed examination. 
  Multiple sclerosis (MS) and its animal model, experi-
mental autoimmune encephalomyelitis (EAE) are chronic 
inflammatory demyelinating diseases affecting the CNS, in 
which the immune system attacks the white matter and even-
tually leads to disability and, at worst, paralysis [6]. While 
much research has been carried out on the progression of 
disease, the exact cause remains unclear. Histopathological 
studies have confirmed that MS lesions are the result of a 
combined insult, involving auto-reactive T cells, B cells, 
macrophages and activated microglia [6-8]. Inflammation in 
areas of the CNS results in the development of random 
‘plaques’, and is followed by the destruction of the myelin 
sheath, a protective coating that surrounds and insulates the 
nerve axon. Myelin is vital for successful nerve signalling; 
its damage leads to impaired signal transduction or blockage, 
resulting in the clinical symptoms of MS (see Fig. 1A) [2]. 
Once the protective sheath is removed or damaged, the nerve 
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is the main determinant of permanent clinical disability, due 
to the limited ability of the CNS to regenerate [9].  
  MS can take the form of primary progressive (PPMS), 
relapsing progressive (RPMS), secondary progressive 
(SPMS) or relapsing remitting MS (RRMS), with the later 
being the most frequently occurring, responsible for 80% of 
cases. Both genetic and environmental factors are thought to 
increase the risk of disease [6]. The prevalence of MS ranges 
between 1 in 500 and 1 in 1500 of the population in Europe, 
North America, and Australasia [10]. No single effective 
drug has been developed to date, and current therapies are 
only partially effective. Two major causes of neurodegenera-
tion and myelin degradation which may be targeted in MS 
therapy are glutamate insult and oxidative stress.  
Oxidative Stress and Glutamate Damage in the MS Brain 
  “Reactive oxygen species” (ROS) are named due to their 
ability to cause oxidative changes within the cell [11]. 
Common cellular free radicals such as the hydroxyl radical 
(OH·), superoxide radical (O2¯·), and nitric oxide (NO·) are 
classified as ROS. Other reactive oxygen species such as 
hydrogen peroxide (H2O2) and peroxynitrate (ONOO) also 
come under the title, because although not free radicals 
themselves, they can lead to the generation of such through 
common chemical reactions [12]. ROS are by-products of 
aerobic metabolism, and are also generated as second mes-
sengers in certain signal transduction pathways. Cells may 
also produce ROS in response to an environmental insult, or 
take up ROS directly from the extracellular fluid. In fact, 
ROS can be created as by-products of many electron transfer 
reactions within the cell or its surrounds, however the major 
source is the mitochondria, as its consumption constitutes 
around 85% of O2 used by the cell. The generation of ROS in 
mitochondria is due to inhibition of the electron transport 
chain, and once generation begins, a positive feedback 
mechanism may occur where existing ROS further hinder 
electron transport, amplifying ROS production. Plasma 
membrane oxidases can also generate ROS during physio-
logical signaling [6, 11].  
  Production of ROS is an essential component of some 
signal transduction pathways, and is crucial for normal cell 
function. ROS are also thought to be involved in the direct 
regulation of transcription factor activity, one example being 
oxidation-reduction of cysteine residues in the DNA binding 
domain [13]. However, during unregulated ROS production, 
excessive or fixed levels of ROS can result in acute damage 
to cellular components, and may lead to cessation of mito-
chondrial energy production. Several antioxidant enzymes 
defend the cell against oxidative damage, the most important 
being catalase, glutathione peroxidase, Cu, Zn-superoxide 
dismutase (CuZuSOD) and Mn-superoxide dismutase 
(MnSOD). These are the body’s natural mechanism of   
protection from oxidation; however these are not always 
sufficient to prevent cellular injury, and may become   
damaged. When the ROS production outweighs these   
enzyme’s ability to defend, the result is known as ‘oxidative 
stress’ (OS) [6, 11].  
  Several characteristics of the central nervous system in-
crease its susceptibility to oxidative stress. The CNS exhibits 
a high metabolic rate and increased ATP synthesis, as well as 
high lipid content and the utilization of dopamine oxidation 
and reactions involving glutamate. The CNS also utilizes a 
large amount of molecular oxygen, and has a limited ability 
for cellular regeneration. These characteristics equate to a 
heightened risk of damage by ROS, and such damage has 
been shown to be implicated in several neurodegenerative 
diseases, as well as neural deterioration in the natural ageing 
process [11]. OS may result in subsequent cell death through 
apoptosis (programmed cell death) and neurodegeneration in 
the CNS due to oxidation of proteins, lipids and DNA [12]. 
Fig. (1B) [6] shows the relationship between oxidative stress, 
glutamate and the CNS.  
  There are various factors contributing to OS in cells, 
however the neurotransmitter glutamate is the primary   
effector within the brain, mainly through the activation of 
ionotrophic receptors. The role of glutamate is illustrated in 
Fig. (1C) [14]. Glutamate and related amino acids are   
released by approximately 40% of all synapses in the   
nervous system, and are responsible for the majority of   
excitatory synaptic activity in mammals [15]. Ionotrophic 
receptors include the main glutamate receptor N-methyl-D-
aspartate (NMDA), -amino-3-hydroxy-5-methyl-4-isoxasole- 
proprionic acid (AMPA) and the kainic acid (KA) family of 
receptors. In MS, glutamate-related excitotoxicity, caused by 
excessive activation of these receptors (leading to a Ca
2+ 
overload), is responsible for neuronal and oligodendrocyte 
death [2, 16, 17]. In addition, microglia, the resident macro-
phages of the CNS, become activated by increased glutamate 
concentration. Activated microglia proliferate, secrete cyto-
kines, chemokines, nitric oxide and ROS, and may become 
phagocytic; outcomes all of which cause further injury to the 
ailing CNS [9]. Oligodendrocytes have been found to be 
particularly susceptible to glutamate excitotoxicity, via  the 
AMPA/kainate receptors. AMPA/kainate antagonists have 
been shown to increase oligodendrocyte survival as well as 
reducing axonal damage [16, 17]. These findings have led to 
the introduction of treatments that block glutamate neuro-
transmission, namely riluzole, which is now a treatment for 
autoimmune demyelination [6, 18].  
Current Therapies  
  Several disease-modifying therapies (DMTs) are   
currently available for the treatment of MS, including two 
formulations of interferon (IFN)--1a (Avonex
® and Rebif
®), 
interferon (IFN)--1b (Betaseron
®), glatiramer acetate (GA) 
(Copaxone
®), and natalizumab (Tysabri
®). Due to the clini-
cal variability and unpredictable nature of MS, prescribing 
treatments for specific individuals is complicated, and while 
all of the above were shown to be partially effective during 
clinical trials, no therapy has the capability to halt disease 
progression [19-21]. Novel neuroprotective and restorative 
strategies are undergoing animal studies and clinical testing, 
such as chemokine-receptor antagonists, which reduce the 
entry of lymphocytes to the CNS, and blockers of neurite 
outgrowth inhibitor, which promote axonal sprouting [22].  
  An amalgamation of cytotoxic cytokines, autoantibodies, 
toxic levels of glutamate and ROS cause damage to myelin, 
neural axons and oligodendrocytes, resulting in the clinical 
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reverse MS, a treatment must simultaneously target a combi-
nation of these factors. The 4 and 7 integrins are thought 
to be significant contributors in the development of MS, 
playing possible roles in inflammation and migration of leu-
kocytes subpopulations across the BBB, and treatment with 
anti- 7 and 4 integrin subunit antibodies has led to accel-
erated improvement and more complete remission in EAE 
subjects [23, 24]. Kanwar et al. [2, 7] devised an approach 
which combines neuroprotection with blockage of inflamma-
tion using MAdCAM-1 antibody (an antibody to the ligand 
for  47), neuroprotector glycine-proline-glutamic acid 
(GPE) and the (AMPA)/kainate receptor antagonist 2, 3-
dihydroxyl-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NQBX). 
The method has shown promise in the treatment of both 
early and advanced stage unremitting EAE, resulting in   
amelioration of disease and repair of the CNS, gauged by 
increased oligodendrocyte survival and remyelination, as 
well as reduced inflammation, apoptosis and axonal damage 
[7]. Administration of either a combination of NQBX and 
GPE or preferably all 3 reagents (NQBX, GPE and anti-
MAdCAM-1) reduce the expression of nitric oxide as well as 
several proinflammatory and immunoregulatory cytokines, 
in particular IL-6, which plays an important role in mediat-
ing EAE. Subjects showed discernible improvements in 
every physical feature examined for 5 weeks, but relapsed 
after suspension of treatment suggesting a requirement for 
ongoing treatment [7]. Further exploration and experimenta-
tion using a multi-faceted approach, inhibiting inflammation 
while simultaneously protecting neurons and oligodendro-
cytes, may lead to the development of effective therapies for 
the treatment of MS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). (A). Schematic of signal transduction in (i) a normal neuron in a healthy brain, versus (ii) a damaged demyelinated neuron in a  
patient affected by MS. In MS the immune system attacks the white matter of the brain in a combined insult involving auto-reactive T cells, 
B cells, macrophages and activated microglia. Inflammation leads to the formation of plaques, followed by the destruction of the protective 
myelin sheath. Myelin damage leads to impaired signal transduction or blockage, resulting in the clinical symptoms of MS. Removal or dam-
age of the myelin sheath leaves the nerve axon exposed and subject to direct injury [24, 29, 31, 43]. (B). The primary sources of ROS and the 
cellular occurrences that may lead to oligodendrocyte and neuronal loss in EAE and MS. Modified from ref. [24]. (C). Autoimmune damage 
causes the supportive astrocytes to be lost or damaged, and repopulation by activated microglia follows. Activated microglia release gluta-
mate, further increasing glutamate levels, which in turn promotes excitotoxic neuronal death by excessive NMDA receptor activation. The 
activation of T-cells specific against CNS-derived antigens follows. T-cells penetrate the BBB and release further glutamate [29, 39, 40, 45]. 
APC= Antigen presenting cell. (D). Possible effects of BARF1 protein on cells of the CNS and proposed mechanisms based on previous 
observations in a variety of cell types. Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr  Current Neuropharmacology, 2010, Vol. 8, No. 3    271 
Epstein-Barr Virus and the BARF1 Oncogene 
  The Epstein-Barr virus (EBV) belongs to family of her-
pes viruses, which persistently infects over 90% of the global 
population [5, 12]. The initial infection usually goes unno-
ticed if contracted in early childhood, but may induce infec-
tious mononucleosis if the first contact occurs during adoles-
cence or adulthood. The virus remains in B cells for the life 
of the individual, and has shown the ability to immortalise 
the lymphocytes in vitro [5]. EBV has been linked to both 
nasopharyngeal carcinoma (NPC) and Burkitt’s lymphoma 
(BL) and is also thought to be associated with subsets of 
other types of carcinomas, such as gastric carcinoma and 
lymphoepithelioma-like carcinoma in the salivary glands and 
the thymus [25]. EBV has been detected in certain types of 
breast tumours, and although it is unlikely to play a primary 
etiologic role in breast cancer, it may contribute to tumour 
progression [26-28]. The virus has also been shown to confer 
resistance to the chemotherapeutic drug Taxol and to induce 
over-expression of the multidrug resistance gene MDR1. It is 
thought that EBV may cause changes in the phenotype of a 
subpopulation of tumour cells, resulting in more aggressive 
behavior [3, 28]. While many links between EBV and cancer 
have been established, the pathogenic role of the virus re-
mains poorly understood.  
  EBV is also hypothesised to trigger several autoimmune 
diseases [29, 30]. Credible prospective seroepidemiological 
studies have consistently verified the relationship between 
EBV and multiple sclerosis, with close to 100% of MS pa-
tients being seropositive for the virus [20, 29, 31, 32]. EBV 
has been speculated as a critical factor for the development 
and progression of MS [20, 29], but its role in the etiology 
and pathogenesis is not well defined. Consistent with suspi-
cion, analyses have shown that the risk of developing MS 
significantly worsens with increased EBV antibody titer, in 
particular, immunoglobulin G (IgG) antibodies binding to 
EBV nuclear antigen 1 (EBNA1) [29, 33]. While several 
possible scenarios regarding the relationship between MS 
and EBV have been proposed, nothing has been substanti-
ated and understanding is lacking [29].  
  The universal positivity of MS patients for EBV is well 
established; hence it is feasible, in terms of treatment, to ex-
ploit an element of the virus itself. A search for a component 
or product of EBV that could be used to the patient’s advan-
tage identified a stand-out: BARF1 protein. Several attrac-
tive properties of BARF1 allude to its potential for therapeu-
tic use. 
  Approximately 90 genes constitute the EBV genome, 
some of which have been studied in depth, with research 
showing strong evidence for oncogenicity [3, 25, 34, 35]. 
Oncogene functions are generally considered to be cell-type 
specific, exhibiting varied effects on different cell lines. 
While the four EBV nuclear antigens EBNA 1, EBNA 2, 
EBNA 3A and EBNA 3C and the latent membrane protein 
LMP1 are required for the immortalisation (continuous 
growth and division) of B lymphocytes in vitro, it is the 
BARF1 gene that is thought to confer this property in epithe-
lial kidney cells and possibly gastric cancer cells [3, 34, 36, 
37]. In rodent cells and human B cell lines Loukes and 
Akata, however, BARF1 appears to induce malignant trans-
formation, the conversion of a previously immortalized cell 
into the malignant phenotype [3]. LMP1 and BARF1 both 
appear to be important effectors in NPC, with the genes be-
ing expressed in 50% and 90% of cases respectively [5]. It is 
thought that the expression of BARF1 may allow generation 
of further ectopic growth or progression to a more advanced 
stage in gastric cancers, and likely plays a similar role in 
other tumours [3].  
  BARF1 is an early gene, transcribed shortly after EBV 
infection from the BAMH1 A fragment of the genome [38]. 
The product is a secretory glycoprotein, consisting of two 
immunoglobulin-like domains [5]. Tarbouriech et al. [5] 
characterised the structure of BARF1, and found that it was 
most closely related to human CD80 (also known as B7-1), 
and has the same topology as the co-stimulatory molecule. 
BARF1 is thought to have been derived from CD80 during 
evolution. Expression cloning has found that BARF1 is a 
functional homologue of the human colony-stimulating fac-
tor receptor, c-fms, allowing it to bind to the hCSF-1 ligand. 
Binding reduces the action of the cytokine on the prolifera-
tion of macrophages [38], as well as the interferon produc-
tion by mononuclear cells [39]. This indicates that BARF1 
protein may also play an immunomodulating role in-situ [5]. 
BARF1 protein has induced cell cycle activation of 
Balb/c3T3 fibroblasts, human B-cells and primary monkey 
epithelial cells, suggesting it may have mitogenic activity on 
certain cells types [5]. Other research has indicated that 
BARF1 may also act as a survival factor, by either suppress-
ing apoptosis or promoting cell proliferation in cell lines [3]. 
Wang and Tsao et al. [3] found that BARF1 expression pro-
motes survival and may confer protection via the inactivation 
of apoptosis pathways. Reduced apoptosis was associated 
with the increased Bcl-2 to Bax ratio, a regulator of cell 
death, which acts by activating or inhibiting procaspase   
activity. 
Neurogenesis and Neuroregeneration: The Possibilities 
and Constraints 
  One limitation in the treatment of neurodegenerative dis-
eases such as MS is the ability of the CNS to regenerate 
damaged or lost neurons. While axonal regeneration occurs 
readily in the peripheral nervous system, it does not take 
place in the CNS to any great extent. This is due to a number 
of factors, but the most prominent is a non-permissive 
growth environment and a lack of appropriate growth factors 
[40]. Spanish scientist and 1906 Nobel Prize winner Ramon 
y Cajal, famous for his pioneering work on the CNS, quoted 
‘in adult centres, the nerve paths are something fixed, ended 
and immutable. Everything may die, nothing may be regen-
erated’. This long-standing dogma has been continuously 
challenged, and it is now known that neural progenitors and 
stem cells in the adult CNS can generate new neurons, astro-
cytes and oligodendrocytes in the subventricular zone 
(SVZ)/olfactory bulb and the dentate gyrus subregion of the 
hippocampus [41]. While this discovery is now widely ac-
cepted as fact, some controversial claims have been made 
relating to the induction of division in mature neurons. 
Brewer [42] declares that mature neurons were effectively 
regenerated in the cerebral cortex of adult rats, while Gu   
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culture [42, 43]. However, the general consensus is that neu-
ron morphology and neurochemical complexity is unrea-
sonably intricate to be maintained during DNA replication 
and nucleus remodeling, although division is theoretically 
possible [41]. Nonetheless, while most reports suggest that 
induction of a mature neuron to re-enter the cell cycle ends 
in failure, the possibly is intriguing, and successful division 
of a differentiated neuron would be a breakthrough in neuro-
science.  
  Despite the slim possibility of differentiated neuronal 
division in vivo, the hope of successful generation, insertion 
and functional integration of new neurons lies with neural 
progenitors and precursors. The manipulation of these cells 
could give rise to exciting new therapies for the treatment of 
degenerative diseases of the brain. Neuronal replacement is 
imperative for full reversal of advanced neurodegenerative 
disease, and the ultimate goal in disease therapy is to wield 
neuronal precursors towards neuronal cell repopulation. 
Some major complications, however, are the limited number 
of resident progenitor, precursor and stem cells in the neu-
ron-producing regions of the brain, their moderate divisional 
activity, and the slow growth of progeny. It would thus be 
feasible to employ a growth factor or mitotic agent, to en-
courage the production and enhance the yield of newborn 
neurons.  
The Therapeutic Potential of BARF1 Protein  
  The previously identified properties of BARF1 protein 
entertain the following question: Does this protein have   
potential for therapeutic use as a survival factor/mitogen/ 
neuroprotector to treat multiple sclerosis or other neurode-
generative or autoimmune diseases? Studies describing the 
neuroprotective ability of BARF1 or use of the protein in the 
CNS are yet to be published, however as discussed previ-
ously, past studies have found other neuroprotectors such as 
GPE and NQBX useful in treating EAE in its early stages 
[7]. While BARF1 protein may act as a survival factor on 
some cell types such as gastric cancer cells, it is not known if 
it will exhibit the same properties when applied to neurons 
and other cells of the nervous system. If it does play and 
anti-apoptotic role in the CNS, this property, combined with 
its possible mitogenic ability, could prove invaluable for the 
treatment of MS. By up-regulating of the production of 
BARF1 protein in MS patients, it may be possible to protect 
components of the CNS against damage inflicted by the im-
mune system, cytokines, ROS and glutamate. The possible 
effects of BARF1 protein on cells of the CNS and proposed 
mechanisms are outlined in Fig. (1D). Hence, the recognised 
properties of BARF1 protein suggest that it may be ideal for 
such application. If BARF1 behaves it the way we anticipate, 
acting as a mitotic and anti-apoptotic agent, it may simulta-
neously protect neurons from stimuli-induced apoptosis, 
while encouraging the growth and proliferation of neurons 
and glia. By incorporating BARF1 into a multi-faceted 
treatment such as that devised by Kanwar et al. (2004), and 
either upregulating its production or using nanoparticle de-
livery, it may prove to be a favourable option indeed, incor-
porating two desired properties into a single therapeutic 
component. Immortalization, malignant transformation and 
immunomodulation are possible properties of BARF1 which 
may prove troublesome in upregulation or vector delivery. 
Due to the inflammatory origins of MS, all care must be 
taken so as not to intensify MS pathology, as blocking the 
proliferation of macrophages and interferon may contribute 
to such. The oncogenic nature of BARF1 also implies that it 
may contribute to tumour cell formation, and while the pre-
vention of apoptosis in cells of the CNS may be beneficial in 
neurodegerative disease, it is also possible that BARF1 will 
prevent cancerous cells from undergoing programmed death, 
but rather allow them to survive and proliferate. Despite 
these risks, the properties of BARF1 appear particularly ap-
pealing for applications in neurodegenerative disease and 
while we must take due caution, the likely benefits suggest 
promising results.  
A Model for CNS Repair 
  Marsupials are born considerably immature and much of 
their development occurs postnataly. Therefore, species such 
as the North American opossum Didelphis virginiana and 
the short-tailed Brazilian opossum Monodelphis domestica 
serve as attractive models in which to study the development 
and repair of motor systems [44-46]. Because the opossum in 
a foetal-like state only 12 days after conception, it possible to 
transect or crush the spinal cord early in development with-
out sacrificing the pregnant opossum or performing intrauter-
ine surgery [44]. This allows observation of CNS repair 
mechanisms, furthering knowledge in this area which could 
possibly lead to improved treatments of spinal trauma pa-
tients and CNS damage.  
  Mammalian experiments involving transection of the 
spinal cord of opossum Didelphis virginiana pups have re-
sulted in normal functionality and use of hind limbs at ma-
turity [46]. When the thoracic spinal cord was transected at 
postnatal day (PD) 5, axons forming all major descending 
and ascending tracts bridge the lesion site. Such growth re-
sulted in remarkably normal hind limb movement in adult-
hood. Similar experiments involving opossum pups at PD 20 
showed growth of descending axons through the transected 
site, but no growth of ascending axons. The pups transected 
at PD20 also showed abnormal functionality and uncoordi-
nated hind limb movement and loss of sensation caudal to 
the lesion. Other experiments involving crushing of the tho-
racic spinal cord on PD7 in Monodelphis resulted in normal 
spinal cord development and functionality at 3 months and at 
maturity. As cell division occurs naturally within the devel-
oping spinal cord (without transection or crushing), neuro-
genesis and gliogenesis observed in these experiments are 
not solely in response to injury. However, increased prolif-
eration in response to lesion was apparent in the meninges, 
but it is not known if meningeal cells contribute to cord re-
construction [46]. Spinal cord tissue regeneration in lower 
vertebrates has been well documented and is dependent on 
the ependymal cell proliferation, as these cells bridge the gap 
at the site of damage before differentiating into new neurons 
and glia [47-51]. There have been reports of mitosis in cells 
which line the central canal after spinal cord injury in post-
natal and adult mammals, but there is little reconstitution of 
new tissue [52, 53].  
  The proliferation of multipotent stem cells in the mam-
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application of such growth factors, as well as possible mito-
genic agents such as BARF1, to the spinal cord lesion of 
these experimental models may result in enhanced recon-
struction and possible improved functionality. By under-
standing the specialised growth environment in which the 
nervous system develops and recreating such in a damaged 
CNS, it may be possible to induce repair in Multiple sclero-
sis patients and those with other neurodegenerative disor-
ders, as well as spinal trauma patients. 
Alternative Therapies and Future Direction for CNS   
Repair 
  Stem cell transplantation, of either embryonic or adult 
origin, represents a promising alternative for the treatment of 
MS [55]. While there are some issues regarding the thera-
peutic use of embryonic stem cells, such as feeder-
independent growth (expansion) and in-vivo teratocarcinoma 
formation, this avenue of treatment is under investigation 
and experts remain positive. Adult or somatic stem cells 
have been widely used in experimental and clinical settings 
showing no significant toxicity or side effects, and without 
tumour formation. Somatic stem cells also appeal due to 
their ready-to-use nature, being derived from different tis-
sues such as the brain [55].  
  A major constraint for stem cell transplantation regards 
the route of administration, which very much depends on the 
lesion site, be it focal or multifocal. Focal CNS disorders 
such as Parkinson’s disease, acute spinal cord injury, brain 
trauma and stroke exhibit anatomo-pathological features and 
may respond to intralesional cell transplantation. The multi-
focality of disorders such as MS and epilepsy require a dif-
ferent approach. Systemic transplantation such as intrave-
nous and intrathecal approaches allow delivery of stem cells 
via  the blood stream or cerebrospinal fluid circulation. In 
these methods the transplanted cells follow a gradient of 
chemo-attractants such as chemokines and pro-inflammatory 
cytokines which occur at the site of inflammatory lesions 
[55-57]. Successful delivery of transplanted neural precursor 
cells (NPCs), hematopoietic (HSCs) and mesenchymal stem 
cells (MSCs) has been achieved in EAE models of MS [55, 
56, 58], as well as spinal trauma [59, 60], epilepsy and stroke 
[61, 62]. The capacity of stem cells to migrate to inflamed 
areas of the CNS and tether, roll and adhere to the inflamed 
endothelial cells is credited to the expression of cell adhesion 
molecules (CAM) and chemokine receptors [55, 56].  
  Transplantation of myelin-forming cells have remarkable 
remyelinating properties, resulting in the restoration of elec-
trophysical nerve function [63], however, the mechanisms as 
to how these transplanted cells exert a beneficial clinical 
effect in EAE are unclear. Mature astrocytes have exhibited 
anti-inflammatory properties in vitro, but did not migrate to 
the brain following intraventricular transplantation, and 
therefore did not reduce brain inflammation or affect the 
clinical course of EAE [64, 65]. The clinical and pathologi-
cal effects of transplanted cells are dependent on their ability 
to migrate to the active inflammatory demyelinated regions. 
Effective migration of NPCs enable their delivery to and 
contact with inflamed tissue, causing suppression of inflam-
mation and reduction of demyelination and axonal injury 
[66]. Transplantation of neurospheres has been shown to 
attenuate the brain inflammatory process in EAE and reduce 
demyelination and axonal injury [66]. 
  Replacement therapies alone may be a satisfactory treat-
ment for accident patients suffering from spinal trauma and 
those who have experienced one-off damage such as stroke 
sufferers; however sufferers of chronic and progressive dis-
eases (MS, Parkinson’s disease etc.) require a more complex 
approach. These patients would need ongoing replacement 
therapy to repair the continual damage afflicted by disease, 
for example oxidative stress and glutamate damage in MS. It 
seems the key to successful CNS repair requires a multi-
faceted approach, combining neuroprotection and blockage 
of inflammation with stem cell replacement or proliferation 
therapies. The benefits of stem cell transplantation may be 
enhanced by combining this therapy with a neuroprotective, 
anti-apoptotic and/or a mitogenic agent. BARF1 protein, 
perhaps possessing two of the above properties of both neu-
roprotection and mitogenic activity, seems an obvious candi-
date in such an approach. With the focus on not one but a 
variety of avenues of treatment, it may be possible to combat 
and overcome neurodegenerative disease. Another benefit of 
the described approach relates to the heterogeneous nature of 
MS: it differs considerably between patients and disease 
categories [2]. The individual components of treatment may 
be varied and tailored for an individual or group; a huge 
benefit in such a diverse and destructive disease. While   
considerable research has been carried out on a diversity   
of cell-based therapies and some neuroprotective and anti-
inflammatory treatments, thorough in-vivo studies must 
completed before all-purpose treatments can become a   
reality. 
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